8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Apr 2, 2026·SEC
Minerva Neurosciences, Inc.(NERV)Earnings, Financials & Key Ratios
NERV•NASDAQ
Price updated Jun 11, 2026
AboutMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$0
- EBITDA-$15M+30.8%
- Net Income-$293M-20492.7%
- EPS (Diluted)-34.67-18347.4%
NERV Key Insights
Minerva Neurosciences, Inc. (NERV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 85 (top 15%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 11.8% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NERV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NERV Price & Volume
Minerva Neurosciences, Inc. (NERV) stock price & volume — 10-year historical chart
Loading chart...
NERV Growth Metrics
Minerva Neurosciences, Inc. (NERV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28947.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15447.37%
Return on Capital
10 Years-38.72%
5 Years-45.19%
3 Years-38.69%
Last Year-23.24%
NERV Recent Earnings
Minerva Neurosciences, Inc. (NERV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026EPS
$0.17
Est $0.13
-30.8%
Revenue
—
Q2 2026
Mar 11, 2026EPS
$0.64
Est $0.11
-481.8%
Revenue
—
Q4 2025
Nov 5, 2025EPS
$0.36
Est $0.35
-2.9%
Revenue
—
Q3 2025
Aug 14, 2025EPS
$0.43
Est $0.95
+54.7%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.17vs $0.13-30.8% | — |
| Q2 2026 | Mar 11, 2026 | $0.64vs $0.11-481.8% | — |
| Q4 2025 | Nov 5, 2025 | $0.36vs $0.35-2.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.43vs $0.95+54.7% | — |
Based on last 12 quarters of dataView full earnings history →
NERV Peer Comparison
Minerva Neurosciences, Inc. (NERV) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 INVA | 1.66B | 22.44 | 6.80 | 18.52% | 118.91% | 47.59% | 0.23 | |
 AXSM | 13.06B | 253.77 | -68.96 | 65.55% | -26.59% | -260.01% | 2.73 | |
 ALTO | 436.7M | 5.65 | 35.31 | -4.9% | 3.16% | 12.53% | 0.40 | |
 NRXP | 67.76M | 3.92 | -2.93 | -10.7% | ||||
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 PTCT | 6.2B | 74.71 | 9.60 | 114.51% | -22.58% | |||
 SNDX | 1.58B | 17.91 | -5.44 | 6.28% | -112.01% | -256.66% | 5.36 |
Compare NERV vs Peers
Minerva Neurosciences, Inc. (NERV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NERV Income Statement
Minerva Neurosciences, Inc. (NERV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 41.18M | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | -100% | - | - | - | - | - |
Cost of Goods Sold | 11.09K | 17.47K | 161.51K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -11.09K▲ 0% | -17.47K▼ 57.4% | -162K▼ 827.5% | 41.18M▲ 25517.3% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | 100% | - | - | - | - | - | - |
Gross Profit Growth % | 32.89% | -57.45% | -827.46% | 25517.28% | -100% | - | - | - | - | - |
Operating Expenses | 41.17M | 51.73M | 75.86M | 39.33M | 45.37M | 25.23M | 23.12M | 21.85M | 15.1M | 27.87M |
OpEx % of Revenue | - | - | - | 95.51% | - | - | - | - | - | - |
Selling, General & Admin | 10.91M | 16.84M | 17.74M | 17.29M | 13.33M | 10.58M | 10.41M | 9.95M | 9.34M | 11.42B |
SG&A % of Revenue | - | - | - | 41.99% | - | - | - | - | - | - |
Research & Development | 30.26M | 34.89M | 58.12M | 22.04M | 32.04M | 14.65M | 12.71M | 11.9M | 5.76M | 5.26B |
R&D % of Revenue | - | - | - | 53.52% | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1000K |
Operating Income | -41.17M▲ 0% | -51.73M▼ 25.6% | -75.86M▼ 46.7% | 1.85M▲ 102.4% | -45.37M▼ 2556.2% | -25.23M▲ 44.4% | -23.12M▲ 8.4% | -21.85M▲ 5.5% | -15.1M▲ 30.9% | -27.87M▲ 0% |
Operating Margin % | - | - | - | 4.49% | - | - | - | - | - | - |
Operating Income Growth % | -36.37% | -25.65% | -46.66% | 102.43% | -2556.18% | 44.38% | 8.37% | 5.5% | 30.87% | - |
EBITDA | -41.16M | -51.71M | -75.7M | 2.02M | -45.26M | -25.22M | -23.09M | -21.83M | -15.1M | -27.87M |
EBITDA Margin % | - | - | - | 4.91% | - | - | - | - | - | - |
EBITDA Growth % | -36.4% | -25.64% | -46.39% | 102.67% | -2337.27% | 44.28% | 8.46% | 5.47% | 30.83% | -27.68% |
D&A (Non-Cash Add-back) | 11.09K | 17.47K | 161.51K | 176.18K | 101.79K | 8.51K | 30.98K | 22.47K | 5.44K | 4.08K |
EBIT | -40.28M | -50.06M | -74.44M | 1.94M | -45.38M | -24.7M | -21.72M | 6M | -293.42M | -306.34M |
Net Interest Income | 327.57K | 1.56M | 1.46M | 0 | -6.31M | -6.85M | -6.85M | -3.29M | 0 | 766.27K |
Interest Income | 941.83K | 1.67M | 1.46M | 0 | 16.52K | 556.95K | 1.44M | 1.27M | 0 | 766.27K |
Interest Expense | 614.26K | 110.45K | 0 | 0 | 6.33M | 7.41M | 8.28M | 4.56M | 0 | 0 |
Other Income/Expense | 270.68K | 1.56B | -17.57M | 94.02K | -6.34M | -6.88M | -6.89M | 23.29M | -278.32M | -387.2M |
Pretax Income | -40.9M▲ 0% | -50.17M▼ 22.7% | -74.44M▼ 48.4% | 1.94M▲ 102.6% | -51.71M▼ 2764.1% | -32.11M▲ 37.9% | -30.01M▲ 6.6% | 1.44M▲ 104.8% | -293.42M▼ 20492.7% | -415.07M▲ 0% |
Pretax Margin % | - | - | - | 4.71% | - | - | - | - | - | - |
Income Tax | -9.38M | 1.67M | -2.25M | 0 | -1.8M | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 22.92% | -3.33% | 3.03% | 0% | 3.49% | 0% | 0% | 0% | 0% | 0% |
Net Income | -31.52M▲ 0% | -50.17M▼ 59.2% | -72.18M▼ 43.9% | 1.94M▲ 102.7% | -49.91M▼ 2671.1% | -32.11M▲ 35.7% | -30.01M▲ 6.6% | 1.44M▲ 104.8% | -293.42M▼ 20492.7% | -415.07M▲ 0% |
Net Margin % | - | - | - | 4.71% | - | - | - | - | - | - |
Net Income Growth % | -1.54% | -59.16% | -43.87% | 102.69% | -2671.15% | 35.66% | 6.55% | 104.8% | -20492.68% | -28947.36% |
Net Income (Continuing) | -31.52M | -50.17M | -72.18M | 1.94M | -49.91M | -32.11M | -30.01M | 1.44M | -293.42M | -415.07M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -6.65▲ 0% | -10.35▼ 55.6% | -14.80▼ 43.0% | 0.38▲ 102.6% | -9.35▼ 2560.5% | -6.01▲ 35.7% | -4.61▲ 23.3% | 0.19▲ 104.1% | -34.67▼ 18347.4% | -9.46▲ 0% |
EPS Growth % | 15.61% | -55.64% | -43% | 102.57% | -2560.53% | 35.72% | 23.29% | 104.12% | -18347.37% | -15447.37% |
EPS (Basic) | -6.65 | -10.35 | -14.80 | 0.38 | -9.35 | -6.01 | -4.61 | 0.19 | -34.67 | - |
Diluted Shares Outstanding | 4.74M | 4.85M | 4.88M | 5.12M | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M | 43.9M |
Basic Shares Outstanding | 4.74M | 4.85M | 4.88M | 5.1M | 5.34M | 5.34M | 6.51M | 7.57M | 8.46M | 43.9M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
NERV Balance Sheet
Minerva Neurosciences, Inc. (NERV) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 129.54M | 90.02M | 47.14M | 27.44M | 62.2M | 40.16M | 42M | 22.27M | 83.1M | 79.11M |
Cash & Short-Term Investments | 128.16M | 88M | 45.85M | 25.36M | 60.76M | 36.09M | 40.91M | 21.36M | 82.3M | 78.16M |
Cash Only | 26.05M | 50.23M | 21.41M | 25.36M | 60.76M | 36.09M | 40.91M | 21.36M | 82.3M | 32.76M |
Short-Term Investments | 102.11M | 37.76M | 24.44M | 0 | 0 | 0 | 0 | 0 | 0 | 45.41M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 80K | 100K | 100K | 100K | 100K | 4.07M | 1.09M | 906.89K | 798K | 941.88K |
Total Non-Current Assets | 54.16M | 49.12M | 30.36M | 30.19M | 14.92M | 14.93M | 14.9M | 14.87M | 14.87M | 14.92M |
Property, Plant & Equipment | 50.95K | 33.48K | 277.96K | 101.79K | 0 | 16.33K | 10.88K | 5.44K | 0 | 0 |
Fixed Asset Turnover | - | - | - | 404.54x | - | - | - | - | - | 0.00x |
Goodwill | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M |
Intangible Assets | 34.2M | 34.2M | 15.2M | 15.2M | 51.08K | 42.57K | 17.03K | 0 | 0 | 0 |
Long-Term Investments | 5.02M | -5.29M | 0 | -2.35M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | -5.27M | 14.81K | 14.81K | 14.81K | 0 | 0 | 0 | 0 | 0 | 50.98K |
Total Assets | 183.7M▲ 0% | 139.14M▼ 24.3% | 77.5M▼ 44.3% | 57.63M▼ 25.6% | 77.12M▲ 33.8% | 55.09M▼ 28.6% | 56.9M▲ 3.3% | 37.14M▼ 34.7% | 97.97M▲ 163.8% | 94.03M▲ 0% |
Asset Turnover | - | - | - | 0.71x | - | - | - | - | - | 0.00x |
Asset Growth % | 38.18% | -24.26% | -44.3% | -25.64% | 33.83% | -28.57% | 3.29% | -34.72% | 163.76% | 95.09% |
Total Current Liabilities | 6.84M | 3.61M | 6.63M | 3.16M | 2.82M | 1.38M | 3.34M | 2.84M | 2.29M | 4.48M |
Accounts Payable | 1.44M | 1.8M | 2.32M | 995.61K | 1.85M | 969.67K | 1.81M | 1.61M | 639K | 2.12M |
Days Payables Outstanding | 47.23K | 37.61K | 5.24K | - | - | - | - | - | - | - |
Short-Term Debt | 3.96M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 41.18B | 41.18B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.43M | 0 | 0 | 31.88K | 0 | 14.83K | 590.77K | 363.18K | -473 | 1.97M |
Current Ratio | 18.94x | 24.94x | 7.11x | 8.68x | 22.07x | 29.15x | 12.57x | 7.85x | 36.29x | 17.65x |
Quick Ratio | 18.94x | 24.94x | 7.11x | 8.68x | 22.07x | 29.15x | 12.57x | 7.85x | 36.29x | 17.65x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 45.26M | 45.26M | 43.09M | 1.8M | 66.33M | 73.73M | 82.02M | 60M | 236.43M | 343.56M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 64.96M | 64.96M |
Capital Lease Obligations | 0 | 0 | 111.23K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 4.06M | 4.06M | 1.8M | 1.8M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 29.88K | 28.99K | 0 | 0 | 66.33M | 73.73M | 82.02M | 60M | 171.46M | 278.6M |
Total Liabilities | 52.1M | 48.87M | 49.72M | 4.96M | 69.15M | 75.11M | 85.36M | 62.84M | 238.72M | 348.04M |
Total Debt | 3.96M | 0 | 284.13K | 111.23K | 0 | 0 | 0 | 0 | 64.96M | 64.96M |
Net Debt | -22.09M | -50.23M | -21.13M | -25.25M | -60.76M | -36.09M | -40.91M | -21.36M | -17.34M | 32.2M |
Debt / Equity | 0.03x | - | 0.01x | 0.00x | - | - | - | - | - | -0.26x |
Debt / EBITDA | - | - | - | 0.05x | - | - | - | - | - | -2.33x |
Net Debt / EBITDA | - | - | - | -12.48x | - | - | - | - | - | -1.16x |
Interest Coverage | -65.58x | -453.25x | - | - | -7.17x | -3.33x | -2.62x | 1.32x | - | - |
Total Equity | 131.6M▲ 0% | 90.26M▼ 31.4% | 27.78M▼ 69.2% | 52.66M▲ 89.6% | 7.98M▼ 84.9% | -20.02M▼ 351.1% | -28.46M▼ 42.1% | -25.69M▲ 9.7% | -140.75M▼ 447.8% | -254.01M▲ 0% |
Equity Growth % | 24.17% | -31.41% | -69.22% | 89.57% | -84.86% | -351.07% | -42.12% | 9.71% | -447.8% | -479.55% |
Book Value per Share | 27.75 | 18.62 | 5.70 | 10.30 | 1.49 | -3.75 | -4.37 | -3.39 | -16.63 | -5.79 |
Total Shareholders' Equity | 131.6M | 90.26M | 27.78M | 52.66M | 7.98M | -20.02M | -28.46M | -25.69M | -140.75M | -254.01M |
Common Stock | 3.88K | 3.89K | 3.91K | 4.27K | 534 | 534 | 699 | 699 | 4.33K | 4.38K |
Retained Earnings | -164.38M | -214.55M | -286.74M | -284.8M | -334.7M | -366.81M | -396.82M | -395.38M | -688.8M | -814.2M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NERV Cash Flow Statement
Minerva Neurosciences, Inc. (NERV) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 3.09M | -41.94M | -43.43M | -33.82M | -24.6M | -24.65M | -14.78M | -19.55M | -13.51B | -5.44B |
Operating CF Margin % | - | - | - | -82.14% | - | - | - | - | - | - |
Operating CF Growth % | 112.04% | -1456.08% | -3.55% | 22.13% | 27.26% | -0.18% | 40.01% | -32.23% | -69007.64% | 94.41% |
Net Income | -31.52M | -50.17M | -72.18M | 1.94M | -49.91M | -32.11M | -30.01M | 1.44M | -293.42M | -415.07M |
Depreciation & Amortization | 11.09K | 17.47K | 161.51K | 176.18K | 101.79K | 8.51K | 30.98K | 22.47K | 5.44M | 4.08K |
Stock-Based Compensation | 5.03M | 8.18M | 9.17M | 9.7M | 5.22M | 4.11M | 1.97M | 1.33M | 1.33B | 8.71B |
Deferred Taxes | -9.38M | -119.61K | -2.25M | 0 | -1.8M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 21.07K | 38.04K | 18.24M | -86.77K | 21.53M | 7.41M | 8.28M | -22.02M | -14.55B | 111.54B |
Working Capital Changes | 38.93M | 110.96K | 3.43M | -45.56M | 259.33K | -4.06M | 4.94M | -320.6K | -632.35K | 2.03M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -32.7K | 364.03K | 517.34K | -1.32M | 857.6K | -883.55K | 835.65K | -197.48K | -1.06M | 1.37M |
Cash from Investing | -107.19M | 69.49M | 14.08M | 24.53M | 0 | -16.33K | 0 | 0 | 0 | -45.29B |
Capital Expenditures | -52.4K | 0 | 0 | 0 | 0 | -16.33K | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 52.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -52.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 47.17M | -3.34M | 525K | 13.24M | 60M | -5 | 19.6M | 0 | 74.45B | 1.15B |
Debt Issued (Net) | -4.94M | -4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 44.56M | 0 | 525K | 12.55M | 0 | 0 | 20M | 0 | 74.45M | 75.62M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -389 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 7.54M | 655.93K | 0 | 687.99K | 60M | -5 | -396.29K | 0 | 74.38B | 1.08B |
Net Change in Cash | -56.93M▲ 0% | 24.2M▲ 142.5% | -28.82M▼ 219.1% | 3.94M▲ 113.7% | 35.4M▲ 797.4% | -24.66M▼ 169.7% | 4.82M▲ 119.5% | -19.55M▼ 505.7% | 60.94B▲ 311803.5% | -49.58B▲ 0% |
Free Cash Flow | 3.04M▲ 0% | -41.94M▼ 1479.5% | -43.43M▼ 3.6% | -33.82M▲ 22.1% | -24.6M▲ 27.3% | -24.66M▼ 0.2% | -14.78M▲ 40.0% | -19.55M▼ 32.2% | -13.51B▼ 69007.6% | -5.44B▲ 0% |
FCF Margin % | - | - | - | -82.14% | - | - | - | - | - | - |
FCF Growth % | 111.84% | -1479.45% | -3.55% | 22.13% | 27.26% | -0.24% | 40.05% | -32.23% | -69007.64% | -27707.39% |
FCF per Share | 0.64 | -8.65 | -8.91 | -6.61 | -4.61 | -4.62 | -2.27 | -2.58 | -1596.28 | -123.84 |
FCF Conversion (FCF/Net Income) | -0.10x | 0.84x | 0.60x | -17.43x | 0.49x | 0.77x | 0.49x | -13.59x | 46.05x | 13.10x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NERV Key Ratios
Minerva Neurosciences, Inc. (NERV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -26.54% | -45.23% | -122.3% | 4.83% | -164.6% | - | - | - | - | 359.8% |
| Return on Invested Capital (ROIC) | -43.73% | -51.89% | -243.78% | 8.13% | - | - | - | - | - | 15.51% |
| Gross Margin | - | - | - | 100% | - | - | - | - | - | - |
| Net Margin | - | - | - | 4.71% | - | - | - | - | - | - |
| Debt / Equity | 0.03x | - | 0.01x | 0.00x | - | - | - | - | - | -0.26x |
| Interest Coverage | -65.58x | -453.25x | - | - | -7.17x | -3.33x | -2.62x | 1.32x | - | - |
| FCF Conversion | -0.10x | 0.84x | 0.60x | -17.43x | 0.49x | 0.77x | 0.49x | -13.59x | 46.05x | 13.10x |
| Revenue Growth | - | - | - | - | -100% | - | - | - | - | - |
Related:NERV Dividend History·NERV Revenue History·NERV Price History·NERV P/E History·NERV Financial Ratios·NERV Institutional Holders
NERV SEC Filings & Documents
Minerva Neurosciences, Inc. (NERV) SEC filings — annual & quarterly reports (10-K, 10-Q)
NERV Frequently Asked Questions
Minerva Neurosciences, Inc. (NERV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Minerva Neurosciences, Inc. (NERV) grew revenue by 0.0% over the past year. Growth has been modest.
Minerva Neurosciences, Inc. (NERV) reported a net loss of $415.1M for fiscal year 2025.
Dividend & Returns
Minerva Neurosciences, Inc. (NERV) had negative free cash flow of $5.44B in fiscal year 2025, likely due to heavy capital investments.